Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down - Here's Why

Key Points

• Shionogi & Co., Ltd. Unsponsored ADR shares experienced a significant gap down, opening at $8.31 compared to the previous close of $8.82, with a trading volume of 2,045 shares.
• The company reported a quarterly earnings per share of $0.16, surpassing analyst expectations of $0.14, but its revenue was lower than expected at $672.90 million against estimates of $719.55 million.
• Shionogi maintains a strong financial position with a debt-to-equity ratio of 0.01 and notable current and quick ratios, suggesting robust liquidity.

Shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $8.82, but opened at $8.31. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.31, with a volume of 2,045 shares.

Shionogi & Co., Ltd. Unsponsored ADR Stock Up 1.6%

The company has a quick ratio of 6.13, a current ratio of 6.63 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average price of $8.49 and a 200-day moving average price of $7.93. The stock has a market capitalization of $14.39 billion, a P/E ratio of 14.30, a PEG ratio of 1.92 and a beta of 0.21.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last released its quarterly earnings results on Monday, July 28th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.14 by $0.02. The company had revenue of $672.90 million during the quarter, compared to analysts' expectations of $719.55 million. As a group, research analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 EPS for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.